Abstract
INTRODUCTION AND OBJECTIVE:Temsirolimus and Everolimus, termed rapalogs, have been used as first generation mTOR inhibitors for renal cell carcinoma (RCC). These rapalogs were designed to block onl...
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
